🇺🇸 FDA
Pipeline program

TD-4208

0135

Phase 1 small_molecule completed

Quick answer

TD-4208 for Renal Impairment is a Phase 1 program (small_molecule) at Theravance Biopharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Theravance Biopharma
Indication
Renal Impairment
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials